Effects of Ticlopidine Administered to Healthy Volunteers on Platelet Function in Whole Blood

Summary

Ticlopidine is thought to be a selective inhibitor of ADP-induced platelet function. Here we have investigated the effects of ticlopidine on platelet function in whole blood induced by ADP and by other platelet agonists. Whole blood was used because it was considered that ADP derived from red cells might act synergistically with other platelet agonists to enhance platelet responses, and that ticlopidine might interfere with this process. Measurements were performed using blood from 16 healthy volunteers before ticlopidine administration, after taking ticlopidine 250 mg daily for 10 days, after taking ticlopidine 250 mg twice daily for a further 10 days, and after 14 days off treatment.

Ticlopidine proved to be a very effective inhibitor of the platelet aggregation induced by ADP; it was most effective in enhancing the reversibility of the aggregation response. The drug modestly but significantly reduced streptokinase, adrenaline, collagen, sodium arachidonate, PAF and U46619 – induced platelet aggregation. The drug significantly reduced the extent of the release reaction (¹⁴C-5HT release) induced by ADP, streptokinase, PAF, ristocetin and sodium arachidonate, and also reduced the extent of the synergistic ¹⁴C-5HT release induced by combinations of ADP and PAF, ADP and adrenaline and PAF and adrenaline.

The various inhibitory effects of ticlopidine were evident after treatment with 250 mg daily but were more pronounced after 250 mg twice daily. All values had returned to normal after 14 days off treatment. Ticlopidine had no effect on serum thromboxane B₂ production nor on several parameters of coagulation and fibrinolysis.

We conclude that ticlopidine is an effective inhibitor of ADP-induced platelet aggregation and also the platelet aggregation and ¹⁴C-5HT release induced in whole blood by a number of platelet agonists and combinations of agonists. These latter effects are probably mainly via a selective effect on ADP. The inhibitory effects of the drug are dose-related.

• References

• 1 Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Malony BA, Anderson S, Kamm B. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New Engl J Med 1989; 321: 501-507
• 2 Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG G. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1215-1220
• 3 Janzon L, Bergqvist D, Boberg J, Boberg M, Eriksson I, Lindgarde F, Persson G. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study J Int Med 1990; 227: 501-508
• 4 SclmӶr K. The basic pharmacology of ticlopidine and elopidogrel. Platelets 1993; 4: 252-261
• 5 Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. Effccts of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther 1975; 18: 485-490
• 6 O’Brien JR, Etherington MD, Shuttleworth RD. Ticlopidine - an antiplatelet drug: Effects in human volunteers. Thromb Res 1978; 13: 245-254
• 7 Ashida S, Abiko Y. Inhibition of platelet aggregation by a new agent, ticlopidine. Thromb Haemost 1978; 40: 542-550
• 8 Hardisty RM, Powling MJ, Nokes TJ C. The action of ticlopidine on human platelets: Studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost 1990; 64: 150-155
• 9 Dembinska-Kiec A, Virgolini I, Rauscha F, Sinzinger H. Ticlopidine and platelet function in healthy volunteers. Thromb Res 1992; 65: 559-570
• 10 Morimoto S, Shiraishi T, Fukuo K, Koh E, Kitano S, Yasuda O, Tamatani M, Ogihara T. Effect of ticlopidine on PDGF release from platelets. Current Therapeutic Research-Clin & Exp 1992; 52: 382-385
• 11 Féliste R, Delebassée D, Simon MF, Chap H, Defreyn G, Vallee E, Douste-Blazy L, Maffrand JP. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res 1987; 48: 403-415
• 12 Cattaneo M, Akkawat B, Lecchi A, Cimminiello C, Capitanio AM, Mannuci PM. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate. Thromb Haemost 1991; 66: 694-699
• 13 Gaarder A, Jonsen J, Laaland S, Hellem A, Owren PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192: 531-532
• 14 Fox SC, Burgess-Wilson M, Heptinstall S, Mitchell JR A. Platelet aggregation in whole blood determined using the Ultra-Flo 100 Whole Blood Platelet Counter. Thromb Haemost 1982; 48: 327-329
• 15 Bevan J, Heptinstall S. Serotonin-induced platelet aggregation in whole blood and the effects of ketanserin and mepyramine. Thromb Res 1985; 38: 189-194
• 16 May JA, Glenn JR, Rajendra B, Sanderson HM, Heptinstall S, Wileox RG. Ticlopidine may interfere with the effects of TXA, on platelet function in while blood as well as those of ADP. Thromb Haemost 1993; 70: 637
• 17 Glenn JR, Heptinstall S, May JA, Sanderson HM, Spangenberg P, Unit E, Wileox RG. Ticlopidine does not inhibit actin polymerization in ADP- activaled human platelets but encourages subsequent depolymerization. Thromb Haemost 1993; 69: 637
• 18 Glenn JR, Spangenberg P, Heptinstall S. Platelet-platelet contact and thromboxane A₂contribute to actin polymerization in platelets stimulated with ADP. Platelets 1994; 5: 84-89
• 19 Mills DC B, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD, Colman RF, Colman RW. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arteriosclerosis and Thrombosis 1992; 12: 430-436
• 20 Savi P, Laplace M-CI, Maffrand JP, Herbert JM. Effect of clopidogrel and ticlopidine on the binding of |3H|-2 methyl-thio-ADP to rat platelets. Thromb Haemost 1993; 70: 637
• 21 Savi P, Laplace M-CI, Herbert JM. Evidence for the existence of two different ADP-binding sites on rat platelets. Thromb Res 1994; 76: 157-169
• 22 Gachet C, Cazenave J-P, Ohlmann P, Bouloux C, Defreyn G, Droit F, Maffrand J-P. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE. Biochem Pharmacol 1990; 40: 2683-2687
• 23 Saniabadi AR, Lowe GD O, Barbenel JC, Forbes CD. A comparison of spontaneous platelet aggregation in whole blood with platelet rich plasma: additional evidence for the role of ADP. Thromb Haemost 1984; 51: 115-118
• 24 Saniabadi AR, Lowe GD O, Barbenel JC, Forbes CD. Further studies on the role of red blood cells in spontaneous platelet aggregation. Thromb Res 1985; 38: 225-232
• 25 Armstrong R, May J, Losche W, Heptinstall S. Factors that contribute to spontaneous platelet aggregation and streptokinase-induced aggregation in whole blood, and approaches to inhibiting these processes. Thromb Haemost 1995; 73: 297-303
• 26 Heptinstall S, Berridge DC, Judge H. Effects of streptokinase and recombinant tissue plasminogen activator on platelet aggregation in while blood. Platelets 1990; 1: 177-188